Search research articles
Contact Us
Filters
Showing results (131-140 of 162) with videos related to
Page
of 17
Sort By:
Gynecologic Oncology
|
September 5, 2001
Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326)
M L Rothenberg, P Y Liu, S Wilczynski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 31, 2010
Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031
V J Picozzi, R A Abrams, P A Decker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2004
A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors
A Craig Lockhart, Martin Howard, Kenneth R Hande, et al.
Cancer Chemotherapy and Pharmacology
|
May 21, 2005
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors
Hiroyuki Kobayashi, S Gail Eckhardt, Jennifer A Lockridge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2007
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models
Jeffrey M Albert, Carolyn Cao, Kwang Woon Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2008
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors
Alejandro D Ricart, Jordan D Berlin, Kyriakos P Papadopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2002
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial
Roy S Herbst, Anne-Marie Maddox, Mace L Rothenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2003
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant
Neal J Meropol, Robert A Somer, John Gutheil, et al.
Oncology (Williston Park, N.Y.)
|
September 3, 1998
Alternative dosing schedules for irinotecan
M L Rothenberg, J G Kuhn, L J Schaaf, et al.
European Journal of Clinical Pharmacology
|
August 31, 2013
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors
Huali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 162) with videos related to
Sort By:
Page
of 17
Gynecologic Oncology
|
September 5, 2001
Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326)
M L Rothenberg, P Y Liu, S Wilczynski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 31, 2010
Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031
V J Picozzi, R A Abrams, P A Decker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2004
A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors
A Craig Lockhart, Martin Howard, Kenneth R Hande, et al.
Cancer Chemotherapy and Pharmacology
|
May 21, 2005
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors
Hiroyuki Kobayashi, S Gail Eckhardt, Jennifer A Lockridge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2007
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models
Jeffrey M Albert, Carolyn Cao, Kwang Woon Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2008
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors
Alejandro D Ricart, Jordan D Berlin, Kyriakos P Papadopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2002
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial
Roy S Herbst, Anne-Marie Maddox, Mace L Rothenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2003
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant
Neal J Meropol, Robert A Somer, John Gutheil, et al.
Oncology (Williston Park, N.Y.)
|
September 3, 1998
Alternative dosing schedules for irinotecan
M L Rothenberg, J G Kuhn, L J Schaaf, et al.
European Journal of Clinical Pharmacology
|
August 31, 2013
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors
Huali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
Page
of 17